California State Teachers Retirement System lifted its holdings in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 1.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 130,075 shares of the biotechnology company’s stock after buying an additional 2,099 shares during the period. California State Teachers Retirement System owned approximately 0.17% of Momenta Pharmaceuticals worth $2,198,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Tortoise Investment Management LLC purchased a new position in Momenta Pharmaceuticals during the second quarter worth about $114,000. Pinebridge Investments L.P. grew its holdings in shares of Momenta Pharmaceuticals by 4.3% in the second quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 363 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in shares of Momenta Pharmaceuticals by 84.6% in the second quarter. State of Alaska Department of Revenue now owns 13,184 shares of the biotechnology company’s stock valued at $222,000 after purchasing an additional 6,044 shares in the last quarter. Profund Advisors LLC grew its holdings in shares of Momenta Pharmaceuticals by 13.1% in the second quarter. Profund Advisors LLC now owns 13,172 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 1,530 shares in the last quarter. Finally, Citigroup Inc. grew its holdings in Momenta Pharmaceuticals by 263.2% during the 2nd quarter. Citigroup Inc. now owns 13,736 shares of the biotechnology company’s stock worth $232,000 after acquiring an additional 9,954 shares in the last quarter. 91.19% of the stock is currently owned by hedge funds and other institutional investors.

MNTA has been the subject of several research analyst reports. Stifel Nicolaus restated a “buy” rating and issued a $26.00 target price on shares of Momenta Pharmaceuticals in a report on Thursday, August 3rd. Cowen and Company set a $15.00 price target on shares of Momenta Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday, November 1st. J P Morgan Chase & Co restated a “hold” rating and set a $14.00 price objective on shares of Momenta Pharmaceuticals in a research report on Thursday, October 5th. BidaskClub cut shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Finally, Goldman Sachs Group, Inc. (The) initiated coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, September 28th. They set a “neutral” rating and a $18.00 price target on the stock. Three analysts have rated the stock with a sell rating and nine have given a hold rating to the company’s stock. Momenta Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $15.00.

ILLEGAL ACTIVITY WARNING: “California State Teachers Retirement System Boosts Stake in Momenta Pharmaceuticals, Inc. (MNTA)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/california-state-teachers-retirement-system-boosts-stake-in-momenta-pharmaceuticals-inc-mnta/1701891.html.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) opened at $12.90 on Tuesday. Momenta Pharmaceuticals, Inc. has a one year low of $11.85 and a one year high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.03. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The firm had revenue of $24.09 million for the quarter, compared to analysts’ expectations of $29.58 million. During the same period in the previous year, the business earned ($0.26) earnings per share. Momenta Pharmaceuticals’s revenue for the quarter was down 17.3% compared to the same quarter last year. equities analysts expect that Momenta Pharmaceuticals, Inc. will post -1.16 earnings per share for the current year.

In related news, President Craig A. Wheeler sold 4,116 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $15.07, for a total value of $62,028.12. Following the completion of the sale, the president now directly owns 269,231 shares in the company, valued at approximately $4,057,311.17. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Craig A. Wheeler sold 35,667 shares of the business’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $19.03, for a total value of $678,743.01. Following the completion of the sale, the president now owns 286,121 shares of the company’s stock, valued at $5,444,882.63. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 61,773 shares of company stock worth $1,111,680. Company insiders own 4.40% of the company’s stock.

Momenta Pharmaceuticals Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.